<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03978039</url>
  </required_header>
  <id_info>
    <org_study_id>IB2012-BCB-SARCOMES</org_study_id>
    <nct_id>NCT03978039</nct_id>
  </id_info>
  <brief_title>National Clinical and Biological Sarcoma Database : An Initiative of the French Sarcoma Group</brief_title>
  <acronym>BCB-Sarcomes</acronym>
  <official_title>The &quot;BCB-sarcomes&quot; Database: the Database of the French Sarcoma Group Dedicated to the Collection of Clinical and Biological Data for All Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French Sarcoma Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Bergonié</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The BCB SARCOMES database is a clinical and biological national database dedicated to sarcoma
      that contains 3 main databases with specific aims: the first is the pathology database
      (French expert network dedicated to the management of bone sarcomas [RESOS] / French expert
      network dedicated to the pathology of sarcomas [RREPS]), dedicated to systematic review of
      mesenchymal tumor diagnostics nationwide; the second is clinical (RESOS / French expert
      clinical network for sarcomas [NETSARC]), collecting multidisciplinary tumor boards (MDTB)
      data of patients nationwide, and the third (CONTICABASE / BONE / GIST) is dedicated to
      collecting patients longitudinal/follow up data, with a focus on treatments of every events,
      and a catalogue of associated samples.

      Primary objectives of BCB-SARCOMES are the following: description of the patterns of care and
      treatment outcomes, assessment of the prognostic factors of patients' outcomes.

      With the financial support of the French National Cancer Institute [Institut National du
      cancer [INCa]).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2010</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Time to next treatment (TNT)</measure>
    <time_frame>2 years</time_frame>
    <description>Time from the systemic treatment onset to the next treatment or death due to any cause, whichever comes first. When neither death nor new systemic therapy is observed, TNT is censored at the date of last patient contact.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to next treatment (TNT)</measure>
    <time_frame>5 years</time_frame>
    <description>Time from the systemic treatment onset to the next treatment or death due to any cause, whichever comes first. When neither death nor new systemic therapy is observed, TNT is censored at the date of last patient contact.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>Interval between diagnosis and the time of death. When death is not observed, OS is censored at the date of last patient contact.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>Interval between diagnosis and the time of death. When death is not observed, OS is censored at the date of last patient contact.</description>
  </primary_outcome>
  <enrollment type="Anticipated">20000</enrollment>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>treatment as per standard of care</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunotherapeutic Agent</intervention_name>
    <description>treatment as per standard of care</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>target treatment</intervention_name>
    <description>treatment as per standard of care</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>treatment as per standard of care</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>treatment as per standard of care</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Sarcoma patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  sarcoma

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maud Toulmonde, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Bergonié, Bordeaux, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Axel Le Cesne, MD/PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Gustave Roussy, Villejuif, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Yves Blay, MD/PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Léon Bérard, Lyon, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maud Toulmonde, MD</last_name>
    <phone>0556333333</phone>
    <email>m.toulmonde@bordeaux.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simone Mathoulin-Pélissier, MD/PhD</last_name>
    <phone>05563333</phone>
    <email>s.mathoulin@bordeaux.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Bergonié, Comprehensive Cancer Center</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maud Toulmonde, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Antoine Italiano, MD/PhD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Yves Blay, MD/PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy, Comprehensive Cancer Center</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel Le Cesne, MD/PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://conticabase.sarcomabcb.org/</url>
    <description>Related Info</description>
  </link>
  <results_reference>
    <citation>Savina M, Le Cesne A, Blay JY, Ray-Coquard I, Mir O, Toulmonde M, Cousin S, Terrier P, Ranchere-Vince D, Meeus P, Stoeckle E, Honoré C, Sargos P, Sunyach MP, Le Péchoux C, Giraud A, Bellera C, Le Loarer F, Italiano A. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Med. 2017 Apr 10;15(1):78. doi: 10.1186/s12916-017-0831-7.</citation>
    <PMID>28391775</PMID>
  </results_reference>
  <results_reference>
    <citation>Toulmonde M, Bonvalot S, Méeus P, Stoeckle E, Riou O, Isambert N, Bompas E, Jafari M, Delcambre-Lair C, Saada E, Le Cesne A, Le Péchoux C, Blay JY, Piperno-Neumann S, Chevreau C, Bay JO, Brouste V, Terrier P, Ranchère-Vince D, Neuville A, Italiano A; French Sarcoma Group. Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. Ann Oncol. 2014 Mar;25(3):735-42. doi: 10.1093/annonc/mdt577.</citation>
    <PMID>24567518</PMID>
  </results_reference>
  <results_reference>
    <citation>Blay JY, Soibinet P, Penel N, Bompas E, Duffaud F, Stoeckle E, Mir O, Adam J, Chevreau C, Bonvalot S, Rios M, Kerbrat P, Cupissol D, Anract P, Gouin F, Kurtz JE, Lebbe C, Isambert N, Bertucci F, Toumonde M, Thyss A, Piperno-Neumann S, Dubray-Longeras P, Meeus P, Ducimetière F, Giraud A, Coindre JM, Ray-Coquard I, Italiano A, Le Cesne A. Improved survival using specialized multidisciplinary board in sarcoma patients. Ann Oncol. 2017 Nov 1;28(11):2852-2859. doi: 10.1093/annonc/mdx484.</citation>
    <PMID>29117335</PMID>
  </results_reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 5, 2019</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>June 28, 2019</last_update_submitted>
  <last_update_submitted_qc>June 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>patterns of care</keyword>
  <keyword>access to care</keyword>
  <keyword>survival</keyword>
  <keyword>experts' network</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

